文献速递免疫规划妇幼与学校卫生

有儿童多系统炎症综合征(PIMS-TS)病史儿童的COVID-19 mRNA BNT162b2疫苗免疫原性研究

COVID-19 mRNA BNT162b2 vaccine immunogenicity among children with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS-TS).
PubMed 文献 · Vaccine · 2023-04-14

前瞻性队列研究纳入20例有PIMS-TS病史的5-12岁儿童和34例无该病史的健康对照,接种两剂COVID-19 mRNA BNT162b2疫苗(10 μg/剂,间隔21天)。接种后抗S IgG几何平均浓度两组无显著差异;混合免疫(无论有无PIMS病史)接种后抗S抗体浓度更高。研究期间PIMS组4例(20%)、对照组11例(32%)感染SARS-CoV-2,均无症状,未显著改变接种后抗S滴度。

要点

  • 有PIMS-TS病史儿童接种BNT162b2后抗S IgG几何平均浓度与健康对照无显著差异。
  • 混合免疫(无论有无PIMS病史)接种后抗S抗体浓度高于疫苗诱导免疫。
  • 研究期间PIMS组4例(20%)、对照组11例(32%)无症状感染,未显著改变接种后抗S滴度。

核心结论

  • COVID-19疫苗接种在儿童中具有高度免疫原性,包括有PIMS-TS病史的儿童。
  • 在儿童中,混合免疫在血清学应答方面优于疫苗诱导免疫。
  • 疫苗预防儿童SARS-CoV-2感染的有效性应进一步评估。

研究设计与样本

  • 前瞻性队列研究,纳入20例有PIMS-TS病史患者(PIMS组,中位年龄7岁,70%男性)和34例无该病史健康对照(CONTROL组,中位年龄8岁,38%男性),年龄5-12岁。
  • 接种两剂COVID-19 mRNA BNT162b2疫苗(Comirnaty®),每剂10 μg,间隔21天。
  • 研究期间为以Omicron变异株为主的COVID-19流行波。

主要发现

  • 接种前抗S IgG血清几何平均浓度:PIMS组61.17 BAU/ml,CONTROL组24.97 BAU/ml;接种后分别为3879.14 BAU/ml和3704.87 BAU/ml,两组间无显著差异。
  • 混合免疫(无论有无PIMS病史)导致接种后SARS-CoV-2抗S抗体浓度更高。
  • 研究期间PIMS组4例(20%)、CONTROL组11例(32%)感染SARS-CoV-2,均无症状,该事件未显著改变接种后抗S滴度。

局限性

  • 疫苗预防儿童SARS-CoV-2感染的有效性应进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We conducted a prospective cohort study of 20 patients with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS group, median age seven years, 70% male) and 34 healthy controls without such a history (CONTROL group, median age eight years, 38% male) aged 5-12 years, to assess the immunogenicity of Pfizer-BioNTech COVID-19 mRNA BNT162b2 vaccine (Comirnaty®). Patients received two doses of COVID-19 mRNA BNT162b2 vaccine (10 ug/dose) 21 days apart. Pre-vaccine anti-S SARS-CoV-2 IgG antibodies were measured on the day of the first dose and at the median of 23 days after the second dose. The study was conducted during the COVID-19 wave dominated by the Omicron variant of the virus. Anti-NCP SARS-CoV-2 IgG antibodies were measured twice to evaluate incidents of infection during the study period. Pre-vaccine quantification of both types of antibodies allowed us to differentiate patients into COVID-19 naive and previously infected in order to compare hybrid immunity with vaccine-induced immunity. Before vaccination, anti-S IgG serum geometric mean concentration (GMC) was 61.17 BAU/ml in the PIMS group and 24.97 in the CONTROL group, while post-vaccination GMC was 3879.14 BAU/ml and 3704.87 BAU/ml, respectively, and did not significantly differ between the groups. Hybrid immunity (regardless of PIMS history) resulted in a higher concentration of SARS-CoV-2 anti-S antibodies after vaccination. Four (20%) of the children in the PIMS group and 11 (32%) in the CONTROL group got infected with SARS-CoV-2 during the study period, yet all of them asymptomatically, and this event has not significantly altered post-vaccination anti-S titers. In conclusion, COVID-19 vaccination was highly immunogenic in children, including those with a history of PIMS-TS; hybrid immunity overperforms vaccine-induced immunity in terms of serological response in children. However, vaccination effectiveness in preventing SARS-CoV-2 infections in children should be further evaluated.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ludwikowska KM, Popiel A, Matkowska-Kocjan A, et al. COVID-19 mRNA BNT162b2 vaccine immunogenicity among children with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS-TS). Vaccine. 2023. PMID: 37087396. doi:10.1016/j.vaccine.2023.04.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。